Gastroesophageal Junction clinical trials

Explore recruiting gastroesophageal junction clinical trials.

Recruiting gastroesophageal junction studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastroesophageal Junction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

Poland, Romania, Germany, Spain, Italy, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Spain, Romania, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer: a phase I study

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.

Norway, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Gastroesophageal Junction trials by city

Gastroesophageal Junction in Toronto Gastroesophageal Junction in Vancouver Gastroesophageal Junction in Montreal Gastroesophageal Junction in Calgary Gastroesophageal Junction in Edmonton Gastroesophageal Junction in Ottawa Gastroesophageal Junction in Winnipeg Gastroesophageal Junction in Quebec City Gastroesophageal Junction in Hamilton Gastroesophageal Junction in Kitchener Gastroesophageal Junction in London Gastroesophageal Junction in Halifax Gastroesophageal Junction in New York Gastroesophageal Junction in Los Angeles Gastroesophageal Junction in Chicago Gastroesophageal Junction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease